Processa Pharmaceuticals, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Processa Pharmaceuticals, Inc. (PCSA) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $7.27 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2024-03-29
- Processa Pharmaceuticals, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2020-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $7.27M.
- Processa Pharmaceuticals, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $0.00.
- Processa Pharmaceuticals, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $7.27M 10-K · filed 2024-03-29 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 10-K · filed 2022-03-30 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 10-K · filed 2022-03-30 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |